Brilacidin HCl

• CAS: 1224095-99-1
• Catalog Number: ACM1224095991
• Category: Others
• Molecular Weight: 1082.75
• Molecular Formula: C40H54Cl4F6N14O6
• Description: Brilacidin, also known as PMX30063, is an arylamide foldamer designed to replicate the amphiphilic properties of antimicrobial peptides while solving the problems encountered by peptide-based antimicrobials. Brilacidin, a broad-spectrum antibiotic, has potent Gram positive activity and Gram negative coverage, and is highly effective in treating the 'superbug' methicillin-resistant Staphylococcus aureus (MRSA). Brilacidin has low cytotoxicity against mammalian cells selectively targeting bacteria, directly and rapidly disrupting their membranes, resulting in the bacteria's death. Due to this unique mechanism of action (mimicking the host's natural immune response, proven to be successful in fighting off infections over millions of years of evolution), bacterial antibiotic resistance is less likely to develop.
• Synonyms: PMX30063; PMX-30063; PMX 30063; Brilacidin; Brilacidin HCl; Brilacidin tetrahydrochloride
• IUPAC Name: N4,N6-bis(3-(5-guanidinopentanamido)-2-(((R)-pyrrolidin-3-yl)oxy)-5-(trifluoromethyl)phenyl)pyrimidine-4,6-dicarboxamide tetrahydrochloride
• Canonical SMILES: O=C(C1=NC=NC(C(NC2=CC(C(F)(F)F)=CC(NC(CCCCNC(N)=N)=O)=C2O[C@H]3CNCC3)=O)=C1)NC4=CC(C(F)(F)F)=CC(NC(CCCCNC(N)=N)=O)=C4O[C@H]5CNCC5.[H]Cl.[H]Cl.[H]Cl.[H]Cl
• InChI: InChI=1S/C40H50F6N14O6.4ClH/c41-39(42,43)21-13-25(57-31(61)5-1-3-9-53-37(47)48)33(65-23-7-11-51-18-23)27(15-21)59-35(63)29-17-30(56-20-55-29)36(64)60-28-16-22(40(44,45)46)14-26(34(28)66-24-8-12-52-19-24)58-32(62)6-2-4-10-54-38(49)50;;;;/h13-17,20,23-24,51-52H,1-12,18-19H2,(H,57,61)(H,58,62)(H,59,63)(H,60,64)(H4,47,48,53)(H4,49,50,54);4*1H/t23-,24-;;;;/m1..../s1
• InChI Key: QTHBCQCKYVOFDR-PIJQHSLXSA-N
• Solubility: Soluble in DMSO, not in water
• Appearance: Solid powder
• Shelf Life: >2 years if stored properly
• Storage: Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
• Alternative CAS: 1224095-99-1 (HCl); 1224095-98-0 (free base)
• Biological Target: Brilacidin tetrahydrochloride (PMX 30063 tetrahydrochloride) is an anti-infective antimicrobial with MIC90s of 1 and 8 μg/mL for Gram-positive bacteria Streptococcus pneumonia and Streptococcus viridans, and MIC90 of 8 and 4 μg/mL for Gram-negative bacteria Haemophilus influenza and Pseudomonas aeruginosa.
• Drug Formulation: This drug may be formulated in DMSO
• Elemental Analysis: C, 44.37; H, 5.03; Cl, 13.10; F, 10.53; N, 18.11; O, 8.87
• Exact Mass: 936.3942
• HS Tariff Code: 2934.99.9001
• In Vitro Activity: The potential of brilacidin to exert an antiviral activity against SARS-CoV-2 was assessed using Vero cells as an infection model. The effect of brilacidin treatment on SARS-CoV-2 viral replication was then evaluated in Vero cells by plaque assay. Vero cells were pretreated with brilacidin for 2 h, after which media containing the drug were removed and replaced with virus inoculum (Washington strain 2019-nCoV/USA-WA1/2020). Infection was allowed to progress for 1 h, after which the inoculum was removed and replaced with brilacidin containing media. The data demonstrate that brilacidin treatment resulted in a dose-dependent decrease in infectious viral titer with a maximum of 53% inhibition of virus observed in the presence of the higher concentration of the compound (10 µM) that was tested; Reference: Viruses. 2021 Feb 9;13(2):271. https://pubmed.ncbi.nlm.nih.gov/33572467/
• In Vivo Activity: Rabbits treated with BRI 1% wiped their eyes immediately upon instillation after the second dose and continued for every dose thereafter. This behavioral reaction suggested that BRI 1% appeared to be irritating to the eyes upon instillation. BRI 1% also demonstrated corneal (median score = 2.5) and iris toxicity (median score = 7.5). One rabbit treated with BRI 0.25%, vocalized shortly after the 5th dose. BRI also 0.5% reduced CFU in abraded corneas significantly more than in intact corneas (P = 0.005, M-W) suggesting that the corneal epithelium acts as a barrier for penetration.; Reference: J Ocul Pharmacol Ther. Jan-Feb 2016;32(1):23-7. https://pubmed.ncbi.nlm.nih.gov/26501484/
• Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
• Stock Solution Storage: 0-4 °C for short term (days to weeks), or -20 °C for long term (months).